Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer – An Overview

被引:0
作者
Aleksandra Tarasiuk
Grzegorz Mirocha
Jakub Fichna
机构
[1] Medical University of Lodz,Department of Biochemistry, Faculty of Medicine
来源
Current Treatment Options in Oncology | 2023年 / 24卷
关键词
Pancreatic cancer; Treatment of pancreatic cancer; Complementary and alternative medicine; Traditional Chinese medicine;
D O I
暂无
中图分类号
学科分类号
摘要
Pancreatic cancer (PC) remains the deadliest cancer worldwide. Most patients are diagnosed at the advanced or metastatic stage, leading to a poor prognosis. Awareness of the limitations of current therapy and accompanying pain, depression, malnutrition, and side effects of chemoradiotherapy may lead patients and physicians towards complementary and alternative medicine (CAM). CAM refers to a diverse set of medical and healthcare practices, products, and systems that are not part of conventional Western medicine. Despite the low-quality evidence supporting the efficacy of these methods, they remain appealing due to patients' beliefs, fear of death, and the slow development of conventional therapy. Hence, the possibility of using natural products for pancreatic cancer is increasing. CAM options such as: medical cannabis, plants, fungi, herbal formulas, and injections, which originate primarily from traditional Chinese or Japanese medicine i.e. Curcuma longa, Panax ginseng, Poria cocos, Hochuekkito, Juzentaihoto, and Rikkunshito, Shi-quan-da-bu-tang/TJ-48, Huang-qin-tang, Shuangbai San, Wen Jing Zhi Tong Fang, Xiang-Sha-Liu-jun-zi-tang, Aidi injection, Brucea javanica oil emulsion/Yadanziyouru injection, Compound Kushen injection, Huachansu injection, Kangai injection and Kanglaite injections are becoming promising candidates for the management of pancreatic cancer. The abovementioned substances/medications are the most popular or potentially effective in PC treatment and consequently CAM-based adjuvant therapy through improving patients’ quality of life, might be a useful addition in the treatment of pancreatic cancer patients.
引用
收藏
页码:1852 / 1869
页数:17
相关论文
共 264 条
[1]  
Rawla P(2019)Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors Rev World J Oncol. 10 10-27
[2]  
Sunkara T(2008)Pancreatic neuroendocrine tumours Eur J Surg Oncol. 34 324-332
[3]  
Gaduputi V(2017)Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis J Cancer 8 3615-3622
[4]  
O’Grady HL(2021)Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection HHS Public Access Gastroenterol. 160 1373-1383
[5]  
Conlon KC(2010)Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer Surg. 8 239-246
[6]  
Meng Q(1990)The clinical utility of the CA 19–9 tumor-associated antigen Am J Gastroenterol 85 350-355
[7]  
Fahrmann JF(2007)Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol. 33 266-270
[8]  
Raptis DA(2021)Pancreatic Cancer: A Review JAMA 326 851-862
[9]  
Fessas C(2023)‘Pancreatic Cancer: A Review of Current Treatment and Novel Therapies J Investig Surg Off J Acad Surg Res. 36 2129884-2406
[10]  
Belasyse-Smith P(2018)FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer N Engl J Med. 379 2395-1585